TL;DR
This study reveals a global decline in bladder cancer burden (incidence, mortality, DALYs) for individuals aged 55+ between 1990 and 2021, driven by factors like aging and population growth, but with significant regional disparities. Despite overall improvements, tailored interventions are crucial to address persistent inequalities, particularly in high-burden areas.
What Problem Does This Paper Address?
Bladder cancer (BC) is a significant public health concern, especially for older adults, due to its prevalence and impact on quality of life and healthcare systems. As life expectancy increases, understanding the long-term trends and regional variations in BC burden among the aging population is critical for effective public health strategies. While previous studies have looked at BC globally, a comprehensive, age-stratified analysis using recent data, particularly for the 55+ demographic, was lacking. This paper aims to fill that gap by providing a detailed, multi-faceted analysis of BC trends, risk factors, and future projections for this specific age group.
Methods
The researchers employed a multi-pronged approach to analyze bladder cancer data:
- Global Burden of Disease (GBD) 2021 Study: This served as the primary data source, providing comprehensive epidemiological data on 371 diseases and 88 risk factors across 204 countries and territories from 1990 to 2021.
- Joinpoint Regression Analysis: Used to identify significant turning points and assess temporal trends in incidence, mortality, and disability-adjusted life years (DALYs) rates, calculating Annual Percentage Change (APC) and Average Annual Percentage Change (AAPC).
- Decomposition Analysis: Employed the Das Gupta method to break down changes in mortality rates into contributions from aging, population growth, and epidemiological changes, allowing for a nuanced understanding of drivers.
- Frontier Analysis: Utilized the Socio-demographic Index (SDI) to evaluate the relationship between BC burden and socioeconomic development, identifying countries with the largest "effective difference" between observed and theoretically achievable minimum DALY rates.
- Bayesian Age-Period-Cohort (BAPC) Model: Used for predicting future BC trends from 2022 to 2036, accounting for age, period, and cohort effects.
- National Health and Nutrition Examination Survey (NHANES): Integrated to analyze specific risk factors, particularly fasting blood glucose and smoking, at an individual level, complementing the GBD data.
- Health Inequality Analysis (HIA): Employed the Slope Index of Inequality (SII) and Concentration Index (CIX) to assess disparities in BC burden across different socioeconomic groups and their trends over time.
Datasets
- Global Burden of Disease (GBD) 2021 Dataset: Encompassing data from 204 countries and territories (1990-2021) for individuals aged 55 and older, including incidence, deaths, and DALYs.
- National Health and Nutrition Examination Survey (NHANES) Database: Utilized eight cycles (2001-2016) of individual-level data from U.S. participants to analyze risk factors like fasting glucose and smoking.
Key Insights and Ideas
- The "Aging Paradox": While overall BC burden is declining, the analysis shows that aging itself, while contributing to fewer new cases, paradoxically drives increases in deaths and DALYs. This highlights the complex interplay of age with disease progression and survival.
- Smoking and Glucose: A Dual Threat: Smoking remains a dominant risk factor, but high fasting glucose is emerging as a significant, preventable contributor, especially in females and older age groups. This suggests a need for integrated public health strategies addressing both.
- Socioeconomic Disparities Persist: Despite some improvements in relative inequality, absolute disparities in BC burden remain, particularly in high-income regions. This points to the need for targeted interventions that go beyond general socioeconomic development.
- Central Europe's Divergent Trend: While many regions show declining mortality, Central Europe stands out with rising mortality and DALY rates, suggesting unique epidemiological transitions or challenges in this region.
- Frontier Analysis Reveals Hidden Potential: The frontier analysis identified countries with significant room for improvement in reducing DALYs, even in some lower-SDI regions, indicating that effective strategies can be implemented regardless of development level.
Key Results
- Incidence Surge, Rate Decline: Global BC cases among individuals aged 55+ more than doubled (113% increase) from 1990 to 2021, yet the crude incidence rate declined slightly (-0.22% APC).
- Mortality and DALYs Downward Trend: Mortality rates dropped from 16.83 to 14.11 per 100,000, and DALYs rates fell from 337.59 to 257.76 per 100,000.
- Gender Disparity: Males consistently bore a 3.8-fold higher incidence burden than females.
- Key Risk Factors: Smoking accounted for 26.6% of DALYs, and high fasting glucose for 8.2%.
- Regional Variations: High-income regions (North America, Western Europe) had the highest incidence but showed downward trends, while Central Europe experienced rising mortality.
- Projected Declines: By 2036, incidence is projected to decrease by 13.3%, mortality by 16.4%, and DALYs by 17.9%.
- Health Inequality: Concentration indices showed a gradual reduction in relative inequality over the period, but absolute disparities persist.
Limitations and Future Work
The authors acknowledge several limitations:
- GBD Data Quality: Reliance on GBD data means accuracy is subject to the availability and quality of national registration data, potentially leading to underdiagnosis or misdiagnosis in low- and middle-income countries.
- Data Lag: GBD data updates have a delay, preventing a full reflection of the most current situation.
- Limited Risk Factor Detail: While key risk factors are identified, the GBD data's focus on overall disease prevents a comprehensive analysis of specific risk factor interactions or causal inferences for all subtypes.
- Subtype Aggregation: The study does not differentiate between specific bladder cancer subtypes (e.g., non-muscle-invasive vs. muscle-invasive), which have different prognoses and treatment needs.
Future work could focus on:
- Granular Subtype Analysis: Investigating trends and risk factors for specific BC subtypes.
- Enhanced Data Integration: Exploring ways to incorporate more detailed, real-time data from national registries or electronic health records.
- Intervention Effectiveness: Evaluating the impact of specific public health interventions (e.g., tobacco control, metabolic syndrome management) in different socioeconomic contexts.
- Personalized Prevention: Developing more personalized prevention and screening strategies based on individual risk profiles, especially for high-risk elderly cohorts.
Summary updated